Literature DB >> 21309995

Clinically important detection of infection as an 'incidental' finding during cancer staging using FDG-PET/CT.

P S Wong1, W F E Lau, L J Worth, K A Thursky, E Drummond, M A Slavin, R J Hicks.   

Abstract

BACKGROUND: FDG-PET/CT is widely used in the management of a variety of malignancies with excellent overall accuracy, despite the potential for false positive results related to infection and inflammation. AIM: As cancer patients can develop clinically inapparent infections, we evaluated the prevalence and nature of incidental findings reported to be suggestive of infections that had been identified during clinical cancer staging with FDG-PET/CT.
METHODS: The study involved a retrospective analysis of 60 patients managed primarily at our facility from a total of 121 cases identified as having possible infection on clinical reporting of more than 4500 cancer staging investigations performed during the calendar year of 2008.
RESULTS: Occult infections were uncommon overall (≤1%), but most often because of pneumonia (31.6%), upper respiratory tract infections (21.1%) or wound infections (15.8%). Abnormal scans contributed to patients' management in 52.7% of cases. Two out of 13 patients whose scan abnormalities were not investigated further had worsening changes on repeated scan and one of these patients had clinical deterioration.
CONCLUSIONS: In patients with FDG-PET/CT scans suggestive of infection and in whom a final diagnosis could be reached, the positive predictive value for FDG-PET/CT scans was 89% suggesting that abnormal scans indicative of infection should be investigated further in this population.
© 2011 The Authors. Internal Medicine Journal © 2011 Royal Australasian College of Physicians.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21309995     DOI: 10.1111/j.1445-5994.2011.02450.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  5 in total

Review 1.  Bacterial Pneumonia in Patients with Cancer: Novel Risk Factors and Management.

Authors:  Justin L Wong; Scott E Evans
Journal:  Clin Chest Med       Date:  2017-03-01       Impact factor: 2.878

2.  Clinical value of FDG-PET/CT in bacteremia of unknown origin with catalase-negative gram-positive cocci or Staphylococcus aureus.

Authors:  Mette Bordinggaard Brøndserud; Court Pedersen; Flemming S Rosenvinge; Poul F Høilund-Carlsen; Søren Hess
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-02-20       Impact factor: 9.236

Review 3.  The impact of infection and inflammation in oncologic 18F-FDG PET/CT imaging.

Authors:  W Tania Rahman; Daniel J Wale; Benjamin L Viglianti; Danyelle M Townsend; Matthew S Manganaro; Milton D Gross; Ka Kit Wong; Domenico Rubello
Journal:  Biomed Pharmacother       Date:  2019-07-01       Impact factor: 6.529

4.  Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis.

Authors:  Gabrielle M Haeusler; Monica A Slavin; John F Seymour; Senthil Lingaratnam; Benjamin W Teh; Constantine S Tam; Karin A Thursky; Leon J Worth
Journal:  Eur J Haematol       Date:  2013-06-15       Impact factor: 2.997

Review 5.  Acute Findings on FDG PET/CT: Key Imaging Features and How to Differentiate Them from Malignancy.

Authors:  Yan Li; Spencer Behr
Journal:  Curr Radiol Rep       Date:  2020-09-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.